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Abstract PGI is a housekeeping gene encoding phosphoglucose
isomerase (PGI) a glycolytic enzyme that also functions as a
cytokine (autocrine motility factor (AMF)/neuroleukin/matura-
tion factor) upon secretion from the cell and binding to its 78
kDa seven-transmembrane domain receptor (gp78/AMF-R).
PGI contains a CXXC motif, characteristic of redox proteins
and possibly evolutionarily related to the CC and CXC motif of
the chemokine gene family. Using site-directed mutagenesis,
single- and double-deletion (CXC, CC) mutants were created
by deleting amino acids 331 and 332 of human PGI, respec-
tively. The mutant proteins lost their enzymatic activity; how-
ever, neither of the deletions augmented the proteins’ binding
a⁄nity to the receptor and all maintained cytokine function.
The results demonstrate that the enzymatic activity of PGI is
not essential for either receptor binding or cytokine function of
human PGI.
3 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
Key words: Phosphoglucose isomerase;
Autocrine motility factor
1. Introduction
Cell migration is an essential aspect of normal and patho-
logical processes, including embryonic development, wound
healing, in£ammation, and tumor cell invasion [1^7]. Auto-
crine motility factor (AMF) is a tumor-secreted polypeptide
identi¢ed by its ability to induce the migration of the AMF-
producing cells [1,8]. Molecular cloning has identi¢ed AMF as
phosphoglucose isomerase (PGI) [1,9], the cytokine neuroleu-
kin [10], the maturation factor [9^13], and the serine protein-
ase inhibitor [14]. PGI (EC 5.3.1.9) catalyzes the interconver-
sion of D-fructose-6-phosphate and D-glucose-6-phosphate
[15]. Inhibitors of PGI isomerase activity are also able to
inhibit its cytokine function [1]. Crystal structures of mamma-
lian and bacterial PGI reveal extensive conservation of the
active site but signi¢cant di¡erences in other regions of the
protein [16^18]. Reports that bacterial PGI stimulates the
motility of murine cancer cells further implicated the sugar-
binding active site in receptor recognition [17^19]. However,
this was challenged based on the demonstration that the cy-
tokine activity of PGI is speci¢c only for the mammalian form
of the enzyme, implying that the active site per se is not
su⁄cient for the cytokine activity of the protein [20].
The receptor for AMF/PGI (gp78/AMF-R) is a seven-trans-
membrane domain G-protein coupled receptor [2,21]. AMF/
PGI therefore resembles members of the CC, CXC gene fam-
ily of chemoattractants, including macrophage in£ammatory
protein-1a (MIF)/RANTES and monocyte chemoattractant
protein-1 (MCP-1), that signal via the CXCR family of
seven-transmembrane domain G-protein coupled receptors
[22,23]. PGI contains a CXXC [Cys330-Phe-Glu-Cys333] motif
also found in the disul¢de isomerase protein family [24] and
MIF [25,26]. Since the integrity of a disul¢de linkage is essen-
tial for MIF activity [27], and reducing agents abolish PGI
function [8], we questioned whether this motif regulates either
the enzymatic or cytokine functions of PGI. Single- and dou-
ble-deletion mutants were created by site-directed mutagenesis
and their biochemical and cellular functions compared to
wild-type (wt) protein. The deletion of either or both amino
acids at the X positions in the CXXC motif a¡ected neither
PGI cytokine activity nor its ability to bind to AMF-R but
did result in loss of isomerase activity. Thus, the cytokine
activity of PGI is independent of the active site of this multi-
functional enzyme.
2. Material and methods
2.1. Cell culture and reagents
Human ¢brosarcoma HT1080 cells were obtained from the Amer-
ican Type Culture Collection (Rockville, MD, USA) and cultivated as
previously described [8]. Mono-speci¢c rabbit polyclonal antibodies
(anti-AMF) were generated as previously described [11]. Fructose-6-
phosphate, NADP, glucose 6-phosphate dehydrogenase, erythrose 4-
phosphate (E4P) was purchased from Sigma (St. Louis, MO, USA).
2.2. SDS^PAGE
The molecular weight of AMF and its mutants was determined by
running 2 Wg of protein on 8% SDS^polyacrylamide gels alongside
prestained molecular weight markers (Gibco-BRL, Bethesda, MD,
USA).
2.3. Co-immunoprecipitation of PGI/AMF and AMF-R
In order to examine whether wt, CC, and CXC bind to the same
receptor, HT1080 cell lysates were immunoprecipitated with anti-
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AMF-R in IP bu¡er (¢nal concentration 1% Triton X-100, 150 mM
NaCl, 10 mM Tris^HCl pH 7.4, 1 mM EDTA, 0.5% NP-40). Samples
were incubated at 4‡C for 2 h. After washing, wt, CC, CXC, or bovine
serum albumin (BSA) (control) was added to each sample and incu-
bated for 2 h at 4‡C with constant rotation. Then 50 Wl of protein A
Sepharose beads was added to each sample for 1 h at 4‡C. Samples
were centrifuged, washed and separated by SDS^PAGE.
2.4. PGI activity
PGI enzymatic activity of puri¢ed recombinant human AMF was
measured as previously described [28].
2.5. Cell motility assays
Random motility was assayed by the phagokinetic method [30].
Directional cell motility assay was measured using a 48-well Boyden
chamber as described in [7].
2.6. Scatchard analysis
Binding of 125I-labeled PGI (iodogen method) to HT1080 cells was
determined and receptor a⁄nity (Kd value) and receptor concentra-
tion (R value) were determined using Scatchard’s method [29].
2.7. Homology modeling and graphic program
The program MODELLER [31] was used for homology modeling
calculations using the crystal structure of inhibitor-free PGI [18] as a
template. Ribbon diagrams were produced with the program View-
erProTM (Accelrys, San Diego, CA, USA).
3. Results
We and others have reported that PGI is a multifunctional
protein [1,9^15]. Here, we questioned the dependence of PGI
cytokine function on its enzymatic activity. Wild-type (wt)
PGI, and single-deletion (CXC) and double-deletion (CC) mu-
tants were constructed, expressed, and puri¢ed as previously
described [32]. As seen in Fig. 1 (panel I), wt, CXC and CC
PGI co-migrate in SDS^PAGE as a single protein band. En-
zymatic analysis revealed that while wt PGI exhibited isomer-
ase activity, both mutants were enzymatically inactive (Fig. 1,
panel II). Next, we questioned whether enzymatic activity is
associated with cytokine activity. Using two independent as-
says to study both random (Fig. 1, panel IIIA) and directional
(Fig. 1, panel IIIB) motility, we found that wt PGI (CXXC)
as well as the CXC and CC mutants at 30 ng/ml all stimulated
the motility of HT1080 cells to the same levels relative to
unstimulated control cells (Fig. 1, panels IIIA and IIIB). In-
terestingly, E4P, a speci¢c PGI enzymatic inhibitor, a¡ected
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Fig. 1. I : Molecular weight determination using SDS^PAGE analysis. Recombinant human PGI protein and its mutant proteins were separated
on 8% SDS gel under reducing conditions. Lane 1, wt; lane 2, CC; and lane 3, CXC. II: Spectrophotometric determination of PGI activity of
wt PGI, CC, and CXC. PGI activity of wt, CC, and CXC was measured at 340 nm on the basis of reduction of NADP to NADPH. The
graph is representative of three independent experiments with similar results. Open square, wt; open circle, CXC; closed square, CC. III: E¡ect
of CXXC (wt), or CC, CXC proteins on the motility of HT1080 cells. A: Phagokinetic analysis. The area cleared by at least 20 cells was deter-
mined. The graph is representative of three independent experiments with similar results using (panel B) Boyden Chamber assay. C: E¡ect of
E4P on the motility induced by CXXC (wt), CC or CXC proteins. The results are expressed as meanQS.D. Random 10 ¢elds were counted.
The results are the meanQS.D. representative of three independent experiments.
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the induction of cell migration of only wt PGI protein with no
e¡ect on either the basal or CC or CXC induced cell migra-
tion (Fig. 1, panel III 3C).
To determine whether the PGI mutants’ cytokine activity
relates to receptor binding, the proteins were incubated with
gp78/AMF-R derived from a lysate of HT1080 cells. AMF-R
was immunoprecipitated with speci¢c antibodies and the pre-
cipitate probed by Western analysis for both PGI and AMF-
R. As seen in Fig. 2, all PGI forms interact with immunopre-
cipitated AMF-R. Next, to establish ligand^receptor binding
constants, Scatchard analysis was performed to determine the
a⁄nity (Kd) and the binding maximum (Bmax) for PGI to its
receptor (Fig. 3). The high a⁄nity binding of wt PGI to its
receptor on HT1080 cells was similar to that observed for the
deletion mutants; however, Bmax was higher for the mutants
than for wt PGI (CXCsCCsCXXC).
The e¡ect of amino acid deletions in the CXXC motif on
three-dimensional models of PGI structure was determined.
Human PGI is a dimer [18] presented as ribbon diagrams
with the two monomers in red and blue and is spherical in
shape (Fig. 4, panel I). Bound inhibitor molecules are shown
in yellow to localize the PGI active site. The CXXC motifs are
shown as ball-and-stick models in green and magenta for the
red and blue subunits, respectively, and are located outside of
the active site of the enzyme. Fig. 4 (panel II) presents a
comparison of the crystal structure of inhibitor-free wt human
AMFR
AMF
1 2 3 4
Fig. 2. Identi¢cation of wt, CC, and CXC binding receptor.
HT1080 cell lysates expressing cell surface AMF-R were incubated
with anti-AMF-R speci¢c antibody and the resulting complex was
incubated with protein A Sepharose beads, centrifuged and washed,
then incubated with wt, CC, CXC AMF/PGI or BSA (control). The
complexes were analyzed by SDS^PAGE for the presence of AMF/
PGI. Lane 1, wt; lane 2, CC; lane 3, CXC; lane 4, BSA.
Fig. 3. Scatchard plot analysis of binding of 125I-labeled wt, CC or
CXC proteins to cell surface AMF-R of HT1080 cells.
Fig. 4. I: Ribbon models showing the location of the CXXC motif
on the crystal structure of wt human PGI dimer. Bound inhibitor
molecules showing the location of the PGI active site are shown as
yellow. The CXXC motifs are shown as ball-and-stick models and
colored green and magenta for ‘red’ and ‘blue’ subunits, respec-
tively. Ia: Top view of the dimer. Ib: Front view. Ic: Side view. II:
Comparison of crystal structure of inhibitor-free wt human PGI
(green) and that of the theoretical model of inhibitor-free double-de-
letion (del. F331G332) mutant of human PGI (red). One subunit is
shown as a ribbon and the other subunit is shown as cylinders (K-
helices) and arrows (L-strands). The N-terminal helices for which a
signi¢cant structural movement is observed are indicated by arrows
(black). The CXXC motif of wt human PGI and the CC motif of
double-deletion mutant of the protein are shown as ball^stick mod-
els and colored cyan and yellow, respectively. IIa: Top view of the
dimer. IIb: Front view. IIc: Side view. IId: Close view of the muta-
tion site. Note that a signi¢cant movement of the N-terminal helix
is observed.
FEBS 26853 6-1-03 Cyaan Magenta Geel Zwart
S. Tsutsumi et al./FEBS Letters 534 (2003) 49^53 51
PGI/AMF (red) and a theoretical model of the inhibitor-free
CC mutant (green). One subunit is shown as a ribbon and the
other subunit is shown as cylinders (K-helices) and arrows (L-
strands). The CXXC motif of wt human PGI/AMF and the
CC motif of double-deletion mutant of human AMF are
shown as ball^stick models and colored cyan and yellow, re-
spectively, and signi¢cant structural movement of the N-ter-
minal helices is predicted (black arrows).
4. Discussion
AMF is a tumor-secreted cytokine that regulates cellular
growth and motility by a receptor-mediated pathway [33]
that is implicated in the most devastating aspect of cancer:
metastasis [34]. The identity of AMF with the ubiquitous
cytosolic enzyme PGI is supported by reports that PGI is
also a neurokine and lymphokine [10,12,35]. However, while
the motifs in the PGI sequence implicated in its enzymatic
activity are well characterized [36] the structural motifs that
regulate its cytokine activity and receptor binding remained to
be determined. The human PGI sequence contains a unique
CXXC motif between amino acids 330 and 333, resembling, in
part, the CXC and CC motifs of MIF and MCP-1 [23,37].
However, deletion mutants of the CXXC intra-domain of this
motif did not result in loss of cytokine activity or binding to
gp78/AMF-R, but did result in a complete loss of the isomer-
ase activity.
PGI is nearly ubiquitous in evolution during which a cluster
of about 40 residues has remained conserved, while most res-
idues outside the active site were altered [31]. It was previously
reported that bacterial PGI exhibited cytokine ability, which,
together with the ability of inhibitors of PGI isomerase func-
tion to block cytokine activity, led to the conclusion that the
substrate and receptor binding sites of PGI are similar or
located within close proximity of each other [17,19]. However,
recently, it was reported that the cytokine function of the
enzyme has evolved during evolution independently of the
enzymatic activity and that the conserved sugar-binding do-
main is not su⁄cient for its cytokine activity [20]. Loss of
enzymatic but not cytokine activity of the CXC and CC mu-
tants con¢rms this result. Furthermore, the failure of the sug-
ar inhibitor to block cytokine activity of the CXC and CC
protein mutants provides the ¢rst direct evidence that the
sugar recognition site of PGI is not critical for ligand^receptor
recognition and that the enzymatic active site is not directly
involved in cytokine activity.
Speci¢c binding of 5-phospho-arabinose involves a network
of polar interactions [16,17,19]. The mammalian-speci¢c
CXXC motif and associated disul¢de bridges are shown
here to be critical for the integrity of the active site of mam-
malian PGI and this motif could therefore be a mammalian-
speci¢c regulator of PGI isomerase activity. Interestingly, mu-
tations associated with hemolytic anemia are found near
the CXXC motif, speci¢cally Leu338, Arg346, Gly323, and
Gln342, and are predicted to disrupt the structure of the
PGI dimer [38]. The proximity of the CXXC motif to the
N-terminal region of PGI is predicted here to induce struc-
tural movement of the N-terminal helices that will a¡ect the
overall conformation of the protein, thereby a¡ecting its iso-
merase activity.
Of note, the overall level of sequence homology between
bacterial and mammalian PGI in the N-terminal region is
quite low and striking structural di¡erences are found in
this region [19]. The N-terminal region as well as the evolu-
tionarily distinct C-terminal domain and peripheral hook and
loop regions are candidates for receptor-interacting domains
of mammalian PGI exhibiting cytokine activity [20]. Addition-
al deletions, mutations or amino acid substitutions in these
regions will be required to directly determine the exact struc-
tural motif controlling receptor binding and cytokine activity
of PGI. To summarize, we provide the ¢rst experimental evi-
dence of dichotomy between the enzymatic and cytokine ac-
tivities of PGI. The fact that local conformation changes due
to condensation of the distance between the cysteine residues
of the CXXC motif of PGI disrupt enzymatic activity but not
receptor interaction shows de¢nitively that the enzymatic ac-
tivity of PGI is not involved in its cytokine function.
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